% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • solantey Feb 28, 2013 8:45 AM Flag

    Short Term Target Price: .45

    .45 may be on the low side.

    Considering the potential impact of the "Human Brain Mapping Project", the investment to date of approximately $35,000,000 in developing the patented MANF technology, and the value attached to Amarantus Diagnostics, and the fact that the GDNF technology sold for $265,000,000 I would attach a current value to Amarantus Bioscience in the $100,000,000 range or about .45/share.

    A joint venture or "big pharma" partnership announcement and the resulting short squeeze could take it much higher but it would probably settle in the .45-.50 range.

    p.s. I'm being very conservative in my approach.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.070.00(+0.08%)May 5 3:54 PMEDT